NANOBIOTIX     EO-,03
NANOBIOTIX EO-,03
Share · FR0011341205 · A1J7EB (XPAR)
Overview Financial Indicators
4,11 EUR
-1,44 % -0,06 EUR
Paris (XLON) · Current prices and charts at MoneyPeak
09.06.2025 08:15

Current Prices from NANOBIOTIX EO-,03

ExchangeTickerCurrencyLast TradePriceDaily Change
XLON: London
London
0QAV.L
EUR
09.06.2025 08:15
4,11 EUR
4,16 EUR
-1,20 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
-1,44 % 10,34 % 35,87 % 30,48 % 34,84 % -23,46 % -63,24 %

Company Profile for NANOBIOTIX EO-,03 Share

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Company Data

Name NANOBIOTIX EO-,03
Company Nanobiotix S.A.
Website https://www.nanobiotix.com
Primary Exchange XPAR Paris
WKN A1J7EB
ISIN FR0011341205
Asset Class Share
Sector Healthcare
Industry Medical - Pharmaceuticals
CEO Mr. Laurent Levy Ph.D.
Market Capitalization 141 Mio
Country France
Currency EUR
Employees 0,1 T
Address 60 rue de Wattignies, 75012 Paris
IPO Date 2014-02-13

Ticker Symbols

Name Symbol
Frankfurt 5NR.F
London 0QAV.L

More Shares

Investors who NANOBIOTIX EO-,03 hold also have the following shares in their portfolio:
PROTAGONIST THERAPEUTICSCS INC
PROTAGONIST THERAPEUTICSCS INC Share
USA 24/29
USA 24/29 Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025